middle.news
Cyclopharm’s Technegas model starts to show its recurring US revenue
10:29am on Thursday 29th of October, 2026 AEDT
•
Healthcare
Read Story
Cyclopharm’s Technegas model starts to show its recurring US revenue
10:29am on Thursday 29th of October, 2026 AEDT
Key Points
Record Q3 US revenue of A$1.62 million, up 124% year on year
84 revenue-generating US systems installed, up 83% in six months
76% of Q3 US sales came from existing-site consumables
186 primary sites in committee review and 71 in contract review
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cyclopharm (ASX:CYC)
OPEN ARTICLE